“Cancer research is asking more of DNA than ever before. Researchers should be able to start with the biological question and access the right synthesis capability as their program develops—from high-diversity early work to dependable manufacturing for larger, longer-term needs. That's what full spectrum means at IDT: helping customers choose the right option for the work in front of them, with room to grow as their needs evolve, backed by the quality and reliability they expect.” —Steven Henck, IDT CTO
🌟Stop by booth #V-2266 to talk with IDT trusted experts at HLTH 2026.🌟
🌟Stop by booth #V-2266 to talk with IDT trusted experts at HLTH 2026.🌟